Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2019-11-25 AGM Information
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
20191212_BOTHE_Convening notice EGM_final.pdf
AGM Information Classification · 98% confidence The document is explicitly titled 'INVITATION TO THE EXTRAORDINARY GENERAL SHAREHOLDERS' MEETING' and details the agenda, proposed resolutions (including capital reduction), voting procedures, and admission requirements for a meeting scheduled for December 12, 2019. This content directly relates to the materials and notices provided for an Annual General Meeting (AGM) or Extraordinary General Meeting (EGM). Since the definition for AGM Information (AGM-R) covers 'Presentations and materials shared during the Annual General Meeting (AGM)', this is the most appropriate classification, even though it is an invitation/notice rather than a presentation itself, as it is the core document governing the meeting.
2019-11-25 English
20191212_BOTHE_Droits actionnaires.pdf
AGM Information Classification · 98% confidence The document is titled 'INFORMATIONS SUR LE DROIT DES ACTIONNAIRES DE POSER DES QUESTIONS A L'OCCASION DE L'ASSEMBLEE GENERALE EXTRAORDINAIRE' (Information on the right of shareholders to ask questions at the Extraordinary General Meeting). It details the procedures, deadlines, and conditions for shareholders to submit written questions prior to an upcoming Extraordinary General Meeting (EGM) scheduled for December 12, 2019. This content directly relates to the procedures and rights surrounding a shareholder meeting, which falls under the scope of AGM Information (AGM-R) or potentially Proxy Solicitation (PSI). Since it specifically details shareholder rights regarding questions for an upcoming general meeting, AGM-R is the most precise fit, as it covers materials shared during or related to the AGM/EGM process.
2019-11-25 French
PR_2019-11-25_BT_EGM_2019-12-12_Notice_EN_Final.pdf
AGM Information Classification · 98% confidence The document is a press release dated November 25, 2019, announcing that the preliminary documents for an Extraordinary General Shareholder Meeting (EGM) scheduled for December 12, 2019, have been made available. It explicitly mentions the notice, agenda, and motions for the meeting are published and available on the website. This content directly relates to soliciting shareholder participation and providing necessary information ahead of a general meeting. This aligns best with the definition of Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to provide information and request votes for meetings. While it announces the availability of documents, the core content is the announcement of the EGM details and where to find the associated materials, making PSI a stronger fit than just RPA (Report Publication Announcement) or AGM-R (which is usually the presentation/minutes *from* the AGM).
2019-11-25 English
PR_2019-11-25_BT_EGM_2019-12-12_Notice_FR_Final.pdf
AGM Information Classification · 95% confidence The document is titled "Mise à disposition des documents préparatoires à l'assemblée générale extraordinaire du 12 décembre 2019" (Making available of preparatory documents for the extraordinary general meeting of December 12, 2019). It explicitly states that the notice of the EGM and the preparatory documents are being made available to shareholders and directs them to the website or requests for copies. This structure—announcing the availability of materials for a shareholder meeting—strongly indicates a communication related to the meeting logistics and documentation, which aligns best with the 'AGM Information' category (AGM-R), even though it is an EGM (Extraordinary General Meeting) rather than an AGM. The content is not the actual voting results (DVA) or the proxy solicitation materials themselves (PSI), but the announcement that the preparatory documents are ready for review prior to the meeting.
2019-11-25 French
20191122_BOTHE_Acte-Notaire.pdf
AGM Information Classification · 96% confidence The document is a formal legal record, specifically a 'procès-verbal' (minutes) drafted by a notary ('notaire') concerning an 'assemblée générale extraordinaire' (Extraordinary General Meeting) of BONE THERAPEUTICS. The agenda explicitly details resolutions regarding the 'RÉDUCTION DES PRIMES D'ÉMISSION ET DU CAPITAL EN APUREMENT DES PERTES' (Reduction of share premiums and capital to write off losses). This type of meeting, which involves major corporate structural changes like capital reduction and statutory amendments, is typically documented in minutes that are either filed as part of a broader corporate governance report or, given the context of shareholder decisions on capital structure, aligns best with filings related to capital changes or governance. Since it is the minutes of a meeting where resolutions were passed (even if the quorum failed for the first attempt, leading to a second meeting announcement), it is a record of a significant corporate action. It is not a standard 10-K, ER, or IR. It is a record of a shareholder meeting, but the core subject is capital structure change. The closest fit among the provided options for a formal meeting record detailing capital structure changes is often related to capital/financing updates or governance. However, the document itself *is* the minutes of the meeting, not just an announcement of the meeting or a proxy statement. Given the content focuses on capital reduction and statutory changes, it relates closely to 'Capital/Financing Update' (CAP) or 'Governance Information' (CGR). Since it is the official record of an Extraordinary General Meeting (EGM) where capital structure was decided, and it is not a DEF 14A (Remuneration) or a standard AGM presentation, it is most accurately classified as a record of a significant corporate action. In many regulatory contexts, minutes of EGMs dealing with capital structure are filed under general corporate actions. Given the options, and recognizing this is the official record of a meeting that addresses capital structure, 'CAP' (Capital/Financing Update) is a strong candidate, but 'AGM-R' (AGM Information) covers general meeting materials. Since this is the *minutes* of an EGM, and not a presentation, 'AGM-R' is slightly less precise than if it were a presentation, but it is the closest fit for a formal meeting record. However, the content is highly specific to capital reduction. Let's re-evaluate: It is the minutes of an EGM. If the meeting had been successful, the resolutions would be implemented. This document records the proceedings of a meeting that addresses capital structure. If we consider the closest fit for formal meeting minutes detailing major corporate restructuring, 'CAP' (Capital/Financing Update) captures the substance of the resolution better than the general 'AGM-R' (which often implies presentations). I will classify it as 'CAP' due to the central theme of capital reduction, which is a financing/capital structure event.
2019-11-22 French
PR_2019-11-06_BT_2019-Q3_EN_Final.pdf
Earnings Release Classification · 100% confidence The document explicitly states it reports 'Financial Results for the First Nine Months of 2019' and provides a 'Business Update for the Third Quarter ended 30 September 2019'. It contains detailed financial highlights (operating loss, cash usage) and operational updates for a specific interim period (nine months/Q3). This structure aligns perfectly with a comprehensive interim or quarterly financial report, which corresponds to the Interim / Quarterly Report category (IR). It is not just an Earnings Release (ER) as it contains detailed financial figures and operational narratives beyond just the initial highlights, nor is it the full Annual Report (10-K). 9M 2019
2019-11-06 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.